Management of neuropathic pain associated with diabetic peripheral neuropathy
• Management of postherpetic neuralgia
• Adjunctive therapy for adult patients with partial onset seizures
• Management of fibromyalgia
• Management of neuropathic pain associated with spinal cord injury
• adjunctive therapy to diet to reduce elevated total cholesterol (total C), LDL, apolipoprotein B (ApoB), non-HDL, and TG levels and to increase HDL in adults with primary hyperlipidemia or mixed dyslipidemia.
• adjunct to reduce total C, LDL and ApoB levels in adolescents.
• Who are at least 1 year after menarchy (women), 10 to 17 years with heterozygous familial hypercholesterolemia (HeFH) and in those who, after dietary treatment, have an LDL >190mg/dl or.
• >160mg/dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors.
• For the treatment of hypertriglyceridemia in adults.
• For the treatment of primary dysbetalipoproteinemia (type III hyperlipoproteinemia).
•Adjunct therapy to other lipid-lowering treatments (e.g., LDL Apheresis) or alone if such treatments are not available to reduce LDL, total C, and ApoB in adults with hypercholesterolemia homozygous familial (HoFH).
• Adjunct to slow the progression of atherosclerosis in adults as
• Part of a treatment strategy aimed at lowering total C and LDL to target levels.
• Reduces the risk of myocardial infarction, stroke and artery Revascularization procedures in people at increased risk of cardiovascular disease.
• adjunctive therapy to diet to reduce elevated total cholesterol (total C), LDL, apolipoprotein B (ApoB), non-HDL, and TG levels and to increase HDL in adults with primary hyperlipidemia or mixed dyslipidemia.
• adjunctto reduce total C, LDL and ApoB levels in adolescents.
• Who are at least 1 year after menarchy (women), 10 to 17 years with heterozygous familial hypercholesterolemia (HeFH) and in those who, after dietary treatment, have an LDL >190mg/dl or.
• >160mg/dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors.
• For the treatment of hypertriglyceridemia in adults.
• For the treatment of primary dysbetalipoproteinemia (type III hyperlipoproteinemia).
•Adjunct therapy to other lipid-lowering treatments (e.g., LDL Apheresis) or alone if such treatments are not available to reduce LDL, total C, and ApoB in adults with hypercholesterolemia homozygous familial (HoFH).
• Adjunct to slow the progression of atherosclerosis in adults as
• Part of a treatment strategy aimed at lowering total C and LDL to target levels.
• Reduces the risk of myocardial infarction, stroke and artery Revascularization procedures in people at increased risk of cardiovascular disease.
• adjunctive therapy to diet to reduce elevated total cholesterol (total C), LDL, apolipoprotein B (ApoB), non-HDL, and TG levels and to increase HDL in adults with primary hyperlipidemia or mixed dyslipidemia.
• adjunctto reduce total C, LDL and ApoB levels in adolescents.
• Who are at least 1 year after menarchy (women), 10 to 17 years with heterozygous familial hypercholesterolemia (HeFH) and in those who, after dietary treatment, have an LDL >190mg/dl or.
• >160mg/dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors.
• For the treatment of hypertriglyceridemia in adults.
• For the treatment of primary dysbetalipoproteinemia (type III hyperlipoproteinemia).
•Adjunct therapy to other lipid-lowering treatments (e.g., LDL Apheresis) or alone if such treatments are not available to reduce LDL, total C, and ApoB in adults with hypercholesterolemia homozygous familial (HoFH).
• Adjunct to slow the progression of atherosclerosis in adults as
• Part of a treatment strategy aimed at lowering total C and LDL to target levels.
• Reduces the risk of myocardial infarction, stroke and artery Revascularization procedures in people at increased risk of cardiovascular disease.
SUPPORT DURING OVARIAN INSUFFICIENCY OR COMPLETE OVARIAN FAILURE IN WOMEN LACKING OVARIAN FUNCTION, LUTEAL PHASE SUPPORT DURING IN-VITRO FERTILIZATION CYCLE, MENACE OF ABORTION OR PREVENTION OF RECURRENT SPONTANEOUS ABORTIONS DUE TO LUTEAL PHASE DEFECT UP TO 12TH WEEK OF PREGNANCY, MENACE OF PRETERM DELIVERY
DISORDERS ASSOCIATED WITH A PROGESTERONE DEFICIT IN PARTICULAR: PRE-MENSTRUAL SYNDROME, MENSTRUAL IRREGULARITIES DUE TO OVULATION DISORDERS OR ANOVULATION, BENIGN MASTOPATHY, PREMENOPAUSE, INFERTILITY CAUSED BY LUTEAL PHASE DEFECT, MENACE OF PRETERM DELIVERY
